Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671370 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16608113 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16601495 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8696423 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21681858 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3154275 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23187612 | 0.86 | HTT (0.57) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL401825 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL524109 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL523692 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| EP-2560978-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-1196169-A4 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1196169-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6291457-B1 | SUBSTITUTED IMIDAZOLE COMPOUNDS | MERCK & CO., INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2001001988-A1 | COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.